Results 131 to 140 of about 131,629 (255)

Renal Hodgkin's disease [PDF]

British Journal of Haematology, 2002
PILATRINO C., CATALDI A., GUERRASIO, Angelo, SAGLIO, Giuseppe   +3 more
openaire   +4 more sources

Enterocolitis associated with glofitamab—First report and clinicopathological findings in three cases

British Journal of Haematology, EarlyView.
Summary Glofitamab is a CD3‐CD20 bispecific antibody used to treat B‐cell non‐Hodgkin lymphoma. We describe three cases of enterocolitis occurring with glofitamab at a single institution. Similarities between cases include onset post cycle 4–5, moderately elevated faecal calprotectin, abnormal bowel avidity on positron emission tomography scan (2/3 ...
Sean McKeague, Molly Robertson, Sam van der Linde, Christine Khoo, Jonathan Segal, Sean Harrop, Adrian Minson, Andrew W. Roberts, Michael Dickinson   +8 more
wiley   +1 more source

Drug Reaction With Eosinophilia and Systemic Symptoms and Severe Drug-Induced Liver Injury After Off-Label Zonisamide Use for Weight Loss. [PDF]

ACG Case Rep J
Sadjadi R, Cogdell E, Mostafa ME, Anatelli F, Ackerman L, Wijarnpreecha K, Han MAT.   +6 more
europepmc   +1 more source

Rare Case of Mantle Cell Lymphoma With Multiple Rectal Lesions

United European Gastroenterology Journal, EarlyView.
Lumir Kunovsky, Eliska Tvrdikova, Jozef Michalka, Jan Trna   +3 more
wiley   +1 more source

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group

British Journal of Haematology, EarlyView.
Summary Developing new therapeutic regimens for relapsed/refractory (R/R) B non‐Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti‐CD20‐containing ...
Charles Herbaux, Emmanuel Bachy, Reda Bouabdallah, Stéphanie Guidez, Olivier Casasnovas, Pierre Feugier, Gandhi Damaj, Hervé Tilly, Loïc Ysebaert, Steven Le Gouill, Nadine Morineau, Emmanuel Gyan, Rémy Gressin, Roch Houot, Morgane Cheminant, Franck Morschhauser, Catherine Thieblemont, Corinne Haioun, Emmanuelle Nicolas‐Virelizier, Luc‐Matthieu Fornecker, Nicolas Daguindau, Guillaume Cartron   +21 more
wiley   +1 more source

Macrophage Activation Syndrome Revealing Hodgkin Lymphoma: A Pediatric Case Report. [PDF]

Cureus
Hared Bouh A, Moussa Sougueh O, Miqdadi A, Al Ammari I, Dini N.   +4 more
europepmc   +1 more source

An international real‐world study of primary vitreoretinal lymphoma from the Australasian lymphoma alliance and collaborators

British Journal of Haematology, EarlyView.
Primary vitreoretinal lymphoma is an incredibly rare non‐Hodgkin lymphoma with no clear international consensus guidelines for diagnosis and management. This study highlights the significant real‐world heterogeneity in diagnostic and management approaches of this rare condition. In particular, the incorporation of systemic therapy to initial management
Catherine Tang, Catriona Downie, Mandeep S. Sagoo, Edward Pringle, Adam Suleman, Katharine L. Lewis, Lucy Zhang, Daire Quinn, L. M. Poon, William Hann, Svetlana Cherepanoff, Luke Coyle, Shireen Kassam, Pamela McKay, Chan Y. Cheah, Anca Prica, Jeffery Smith, Nada Hamad   +17 more
wiley   +1 more source

Tailored Therapeutic Approach in a Patient With Diffuse Large B-Cell Lymphoma With Meningeal Infiltration, Concurrent Classic Hodgkin Lymphoma, and Smoldering Multiple Myeloma: A Case Report. [PDF]

Cancer Rep (Hoboken)
Ceparano G, Lorenzini D, Ponzoni M, Levati G, Epifania D, Marasco V.   +5 more
europepmc   +1 more source

Hodgkins Disease and Pregnancy [PDF]

Acta Radiologica, 1950
openaire   +5 more sources

The role of blinatumomab in adult acute B lymphoblastic leukaemia

British Journal of Haematology, EarlyView.
Blinatumomab, a CD19‐directed bispecific T‐cell engager, has become a crucial part of BCP‐ALL therapy in r/r disease, MRD‐positive disease and has recently been implemented into first‐line therapy of BCP‐ALL. This review discusses important clinical trials with a focus on blinatumomab in first‐line therapy of adult BCP‐ALL.
Anne C. Wilke, Nicola Gökbuget
wiley   +1 more source